Engineered insulin secretion from neuroendocrine cells isolated from human thyroid.

Area of Science:

• Endocrinology
• Cell Biology
• Regenerative Medicine

Background:

• Type 1 diabetes involves autoimmune destruction of insulin-producing beta cells.
• Human thyroid neuroendocrine (NE) cells are explored as an alternative cell source.

Purpose of the Study:

• To engineer human thyroid NE cells to secrete insulin, respond to glucose, and evade autoimmune attack.
• To assess the feasibility of using these modified cells for diabetes treatment.

Main Methods:

• Thyroid tissue isolation and cell sorting.
• Transduction of NE cells with viral vectors encoding insulin and key transcription factors (PDX1, NGN3, MAFA, HNF6).
• Assessment of insulin secretion, storage, and gene expression changes.

Main Results:

• Isolated thyroid NE cells expressed neuroendocrine markers and secreted Gastrin-Releasing Peptide (GRP).
• Engineered cells produced and secreted human insulin, with insulin localized to secretory vesicles.
• Overexpression of transcription factors enhanced expression of beta-cell and glucose-sensing genes.

Conclusions:

• Human thyroid NE cells can be modified to produce and store insulin.
• Transcription factor manipulation promotes beta-cell-like characteristics and glucose responsiveness.
• Engineered autologous thyroid NE cells represent a promising therapeutic strategy for type 1 diabetes.